Corporate Overview

Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2013 sales of $15.3 billion and has approximately 61,500 employees.

Business Overview

BioScience
2013 Sales-$6.6 Billion

Baxter is a leading manufacturer of recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines.

Medical Products
2013 Sales-$8.7 Billion

Baxter’s Medical Products business manufactures products used in the delivery of fluids and drugs to patients. These include intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, Baxter's Medical Products business is a leader in Renal home-based therapies, such as peritoneal dialysis, and offers other products and services for people with end-stage kidney disease.

 

2013 Sales by Business

2013 Sales by Region

  regional_employee_breakdown

Regional Employee Breakdown

   
2011
2012
2013
United States  
19,000
20,300 
22,000
Europe  
15,000
15,500
21,000
Latin America/Canada  
6,660 
6,875
8,500
Asia Pacific  
7,600 
8,100
9,700
Total  
48,500 
50,800
61,500

R&D Expenditures (in millions)

Because of our longstanding commitment to research and development, Baxter’s history is rich with medical firsts, from the first commercially manufactured intravenous (IV) solutions to the first portable kidney dialysis machine, plus many more. Baxter continually pursues breakthrough technologies through research facilities around the world, and our investments reflect that commitment.

Learn more

Access the materials below to learn more about Baxter's global business seen through the lives of patients around the world.


In 2011, Gilberto Jimenez Chavez of Mexico City experienced extreme bleeding during surgery to remove a brain tumor. Surgeons used Baxter's FLOSEAL to help control the bleeding.